Why Celgene Therapeutics?
At Celgene, we take special care to provide patients safe access to our treatments. We have developed unique, industry-leading programs under which hundreds of thousands of patients worldwide have accessed the clinical benefits of our therapies. At Celgene, we are focused on providing patients with safe access to our treatments.
What happens once Otezla is approved by the patient's health plan?
Once Otezla is approved by the patient's health plan, the patient is no longer eligible for the Bridge to Commercial Coverage Offer. (See PROGRAM DETAILS in full Terms & Conditions.) Co-Pay Offer: If Otezla is approved by the patient's health plan, a patient can pay as little as a $0 co-pay per month for their Otezla monthly out-of-pocket costs.
What is Celgene's clinical trial management policy?
Celgene is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) and is compliant with Principles for Responsible Clinical Trial Data Sharing and is compliant with regulatory requirements for registration and results posting.
What is Celgene's special care?
What is Celgene's mission?
What is Celgene's major investment?
Is Celgene a member of the European Federation of Pharmaceutical Industries and Associations?
See 1 more
About this website
How do you get Otezla covered?
Otezla is covered by most health plans in the US, including commercial, Medicare, and Medicaid....FINANCIAL SUPPORTPatients with commercial health insurance plans.Patients covered by Medicare and Medicaid.Patients without health insurance coverage.Underinsured patients.
What is the Otezla bridge program?
The program provides up to a Maximum Program Benefit of assistance to reduce a patient's out-of-pocket prescription costs that Amgen will provide per patient for each calendar year, which must be applied to the Otezla patient's out-of-pocket costs (co-pay, deductible, or co-insurance).
How much is Otezla at Walmart?
Average 12 Month Prices for OtezlaPharmacyOtezla Retail PriceOtezla SingleCare PriceWalmart$4585.98$3790.94Walgreens$5011.37$4087.37Kroger Pharmacy$5091.00$3910.20Albertsons Pharmacy$4531.20$4047.601 more row
When will Otezla go generic?
Is there a generic for Otezla? There is currently no generic version of Otezla on the market, and there likely won't be one until at least 2028.
What medications make Otezla less effective?
Other medications can affect the removal of apremilast from your body, which may affect how apremilast works. Examples include certain drugs used to treat seizures (such as carbamazepine, phenobarbital, phenytoin, primidone), rifamycins (such as rifampin, rifabutin), among others.
Does Otezla cause weight loss?
Loss of appetite and weight loss are common side effects of Otezla. Weight loss can occur in 10% to 12% of people who take it. The loss of 5% to 10% of body weight is most common, but some people have had weight loss of over 10% of their body weight.
Do you take Otezla forever?
For some people, Otezla can prevent symptoms of psoriasis or psoriatic arthritis without causing any problematic side effects. In this case, the drug may be continued long-term to keep the condition under control. Long-term studies, ranging from 3 to 5 years, have shown that Otezla is safe for prolonged use.
What tier drug is Otezla?
What drug tier is Otezla typically on? Medicare prescription drug plans typically list Otezla on Tier 5 of their formulary. Generally, the higher the tier, the more you have to pay for the medication.
Can you drink alcohol on Otezla?
While there is no direct interaction between Otezla and alcohol, it is not recommended to drink alcohol while taking Otezla. Otezla and alcohol consumption could lead to worsened side effects. Many people are aware that drinking alcohol alone can lead to nausea, vomiting, diarrhea, and indigestion.
What is stronger than Otezla?
In clinical trials*, Stelara proved to be slightly more effective than Otezla when used to treat both types of psoriasis.
What's the difference between Humira and Otezla?
One main difference between Otezla and Humira is how they're given. Otezla comes as a tablet that you take by mouth twice per day. Humira, on the other hand, comes as a liquid given by subcutaneous injection (an injection given under the skin).
What are the risks of taking Otezla?
Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of complications from having severe diarrhea, nausea, or vomiting.
How many days does an Otezla starter pack last?
Otezla is available as a 14-day or 28-day starter pack to make it easy to start treatment.
Can I restart Otezla?
You should never stop taking Otezla without talking with your doctor. Although stopping Otezla doesn't cause symptoms, stopping and restarting the medication increases your risk for side effects.
How long does Otezla starter pack last?
Otezla Starter Pack (14-day or 28-day) 1.
How do I get Otezla starter pack?
Patients can enroll/re-enroll by calling 1-844-4OTEZLA (1-844-468-3952) or by going to Otezla.com/copay.
NeedyMeds
Eligibility Requirements : Insurance Status: Determined case by case: Those with Part D Eligible? Contact program for details. Income: At or below 650% of FPL
Celgene Patient Support Enrollment Form - RxHope
Celgene Patient Support® Enrollment Form Phone: 1-800-931-8691 Web site: www.celgenepatientsupport.com Fax: 1-800-822-2496 E-mail: [email protected]
Lenalidomide REMS® Program | REVLIMID® (lenalidomide)
REVLIMID ® (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells). REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless ...
Prescriber Enrollment Form - REMS Revlimid
All prescribers must be certified to prescribe REVLIMID® (lenalidomide). To become certified the prescriber must: 1. Complete the Prescriber Enrollment Form, which is required for REVLIMID REMS® (formerly known as the RevAssist® program) certification. 2.
Register Your Patient Organization | Celgene Corp.
Please complete the following information about your patient organization so that we can keep in touch with you about our patient advocacy activities and Celgene information as it relates to your organization.
What is Celgene's special care?
At Celgene, we take special care to provide patients safe access to our treatments. We have developed unique, industry-leading programs under which hundreds of thousands of patients worldwide have accessed the clinical benefits of our therapies.
What is Celgene's mission?
Across Europe, Celgene provides support to organizations and initiatives that make a positive impact on our patients, our communities and our world, today and for years to come. We are committed to improving the lives of patients and focus our support in areas where we can make the greatest impact.
What is Celgene's major investment?
Celgene invests significant resources into the research and development of disease altering therapies for cancer and other serious immune-inflammatory conditions.
Is Celgene a member of the European Federation of Pharmaceutical Industries and Associations?
Celgene is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) and is compliant with Principles for Responsible Clinical Trial Data Sharing and is compliant with regulatory requirements for registration and results posting.
When will Celgene approve OTEZLA?
Celgene anticipates a regulatory decision for OTEZLA in oral ulcers associated with Behçet’s Disease from the Pharmaceuticals and Medical Devices Agency in Japan in the second half of 2019. The Company also submitted a Type II Variation to the Marketing Authorization Application earlier this year seeking approval in the European Union.
What is OTezla approved for?
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease. With this third indication in the U.S., OTEZLA is the first and only treatment approved for oral ulcers associated with Behçet’s Disease.
How effective is otezla?
The FDA approval was based on efficacy and safety results from the randomized, placebo-controlled, double-blind Phase 3 RELIEF™ study evaluating OTEZLA in 207 adult patients with Behçet’s Disease with active oral ulcers who were previously treated with at least one nonbiologic medication and were candidates for systemic therapy. Results showed OTEZLA 30 mg BID resulted in a 42.7 point reduction from baseline in the pain of oral ulcers as measured by the visual analog scale (VAS) at week 12, compared with an 18.7 point reduction with placebo. The proportion of patients achieving an oral ulcer complete response (oral ulcer-free) at week 12 was 52.9% in the OTEZLA arm and 22.3% in the placebo arm. The proportion of patients achieving oral ulcer complete response by week 6 and who remained oral ulcer-free for at least six additional weeks during the 12-week treatment phase was 29.8% in the OTEZLA arm and 4.9% in the placebo arm. The daily average number of oral ulcers during the 12-week treatment phase was 1.5 in the OTEZLA arm and 2.6 in the placebo arm (based on oral ulcer counts measured at baseline and at weeks 1, 2, 4, 6, 8, 10 and 12).
How many patients are prescribed otezla?
Since its initial FDA approval in 2014, OTEZLA has been prescribed to more than 250,000 patients with moderate to severe plaque psoriasis or active psoriatic arthritis in the U.S. 4. OTEZLA is available in the U.S. and is dispensed through a comprehensive network of specialty pharmacies.
How much weight loss is associated with Behçet's disease?
Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo.
Is the OTEZLA study placebo controlled?
The RELIEF™ study is a Phase 3 randomized , placebo-controlled, double-blind study evaluating OTEZLA 30 mg BID in 207 adult patients with Behçet’s Disease with active oral ulcers who were previously treated with at least one nonbiologic medication and were candidates for systemic therapy. This 64-week study was conducted at 53 sites across 10 countries.
Is OTezla approved for psoriatic arthritis?
OTEZLA is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet’s Disease.
IMPORTANT SAFETY INFORMATION
Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized.
INDICATIONS
Otezla ® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
What is Celgene's special care?
At Celgene, we take special care to provide patients safe access to our treatments. We have developed unique, industry-leading programs under which hundreds of thousands of patients worldwide have accessed the clinical benefits of our therapies.
What is Celgene's mission?
Across Europe, Celgene provides support to organizations and initiatives that make a positive impact on our patients, our communities and our world, today and for years to come. We are committed to improving the lives of patients and focus our support in areas where we can make the greatest impact.
What is Celgene's major investment?
Celgene invests significant resources into the research and development of disease altering therapies for cancer and other serious immune-inflammatory conditions.
Is Celgene a member of the European Federation of Pharmaceutical Industries and Associations?
Celgene is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) and is compliant with Principles for Responsible Clinical Trial Data Sharing and is compliant with regulatory requirements for registration and results posting.
